The study compared the effectiveness and safety of budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in patients with COPD. The findings indicated that budesonide-glycopyrrolate-formoterol was associated with a higher incidence of moderate or severe COPD exacerbations compared to fluticasone-umeclidinium-vilanterol. However, the incidence of admission to hospital with pneumonia was similar between the two treatments. The study suggested that fluticasone-umeclidinium-vilanterol may be a safe and effective alternative to budesonide-glycopyrrolate-formoterol, especially for health systems aiming to reduce the use of metered dose inhalers due to their environmental impact. Further research is needed to confirm these findings.
Source link
Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study
